B
lood pressure (BP) control has been associated with an approximately 40% reduction in the risk of stroke and an approximately 15% reduction in the risk of myocardial infarction. 1 Angiotensin-converting enzyme inhibitors (ACEIs) are one of the first-line agents for the treatment of hypertension. 2 By blocking the active site of angiotensinconverting enzymes, these agents decrease angiotensin II (AngII) levels, thereby lowering BP. 3, 4 However, the BP response to ACEI varies markedly among individuals and among different ethnic groups. 5, 6 Such variations suggest that the genetic constitution of an individual may play a major role in the BP response to ACEI therapy.
Candidate genes for the pharmacogenetics of ACEI therapy include genes in the renin-angiotensin pathway. The
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angiotensinogen (AGT) gene, one of the major structural genes in this pathway, has been associated with hypertension, 7 and the AGT single-nucleotide polymorphisms (SNPs) M235T(rs699), M174T(rs4762), and A-6G(rs5051) have been associated with serum AGT levels. 8 -13 AGT SNPs also have been associated with BP-related phenotypes within different ethnic groups 14, 15 and have been tested for their association with responses to many hypertensive therapies such as diuretics, ß-blockers, angiotensin receptor blockers, calcium channel blockers, and ACEIs, but the results have been inconsistent. 16 The actions of AngII are mediated by AngII receptors. The major receptor is the AngII type I receptor (AGTR1), which mediates the major biological actions of AngII, including vascular contraction, pressure responses, renal tubular sodium transport, and aldosterone secretion. 17, 18 Another receptor, the AngII type II receptor (AGTR2), is the minority subtype with relatively lower expression in adult tissue. 19 AGTR2 is thought to be a vasodilator and antigrowth effector. 20 AGTR1 [21] [22] [23] and AGTR2 24, 25 variants have been associated with hypertension and with responses to antihypertensive therapy, but these results also have been inconsistent. 26 -29 The aim of the present study was to test several AGT, AGTR1, and AGTR2 SNPs for their association with BP reduction in response to ACEIs, analyzing SNPs as well as haplotypes in a large ACEI postmarket surveillance trial among the Chinese population.
Methods

Subjects
Subjects were recruited from the 3-year postmarketing surveillance of benazepril, an ACEI, within the Chinese Community-Based Comprehensive Prevention and Control of Hypertension project, 30 a study of 34 770 permanent residents Ն35 years old in the Nanshi District of Shanghai, Values are expressed as mean (SD) or percent. SBP indicates systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; CR, serum creatinine; and BUN, blood urea nitrogen.
All P values Ͼ0.05. *Antihypertensive treatment before angiotensin-converting enzyme inhibitor therapy. *The haplotypes were constructed in the order of the single-nucleotide polymorphisms as rs4762(C/T), rs699(C/T), and rs7079(C/A) for the AGT gene and rs1492078(T/C), rs2638362(C/T), rs2640543(G/A), rs389566(T/A), rs275649(G/A), rs5182(T/C), and rs5186(A/C) for the AGTR1 gene. Only haplotypes with haplotype frequency Ͼ3% are listed.
China. All participants in the Chinese Community-Based Comprehensive Prevention and Control of Hypertension project were screened for BP and medical history by a standard questionnaire. Baseline BP was measured in the morning (9 to 12 AM) for most of the patients (80%), using standard methods. Hypertension was defined as mean diastolic BP (DBP) Ն90 mm Hg, mean systolic BP (SBP) Ն140 mm Hg, or current use of antihypertensive medication. Exclusion criteria included recent myocardial infarction, stroke, uncontrolled angina within the past 3 months, and severe liver or renal disease. Hypertensive patients with written informed consent were recruited into this surveillance trial and were observed for 3 years.
Benazepril hydrochloride (Lotensin; Novartis AG, Basel, Switzerland) was given to participants to control BP to less than 140/ 90 mm Hg. The initial daily dosage was either 5 mg for patients with mild hypertension or 10 mg for patients with moderate and severe hypertension, and patients were then evaluated every 2 weeks for 8 weeks to obtain the target BP with the minimum required dose. At each follow-up visit, if the target BP level had not been reached, an increment of 5 mg/d was added until the target BP was achieved or the dosage reached 20 mg/d (Table 1) . For those who still did not reach the BP target level at 20 mg/d, dihydrochlorothiazide was added. Patients were considered nonresponders to trial medication if they had not reached the target BP level at the end of 12 weeks after the above treatment; these patients were excluded from the trial. As a result, 1831 patients were included in the trial. The blood samples of 1831 subjects were collected at the first visit, tested for serum creatinine and blood urea nitrogen, and stored for deoxyribonucleic acid extraction. Of these, a subset (nϭ1501) had sufficient deoxyribonucleic acid samples for genotyping. There was no significant difference between the subjects with and without deoxyribonucleic acid samples for gender, age, smoking, body mass index, baseline BP, dose, or BP reduction (data not shown). The 54 patients treated with dihydrochlorothiazide were excluded. Reduction in BP was defined as the difference between the baseline BP and BP from the last visit for patients without any adverse effects. For patients with adverse effects, and to reduce confounding attributable to changes in the dose of benazepril to manage patient health, the BP from the last visit before the onset of the adverse effect was used to calculate reduction. All research was approved by the institutional review boards of Cedars-Sinai Medical Center and Peking University.
SNP Selection and Genotyping
As shown in Figure 1 , 14 SNPs from AGT, AGTR1, and AGTR2 were selected (1) to tag common genetic variation in the Caucasian and African American populations using resequencing information generated at the University of Washington, Seattle, for an associated project, the Pharmacogenetics of Atherosclerosis Risk of Cardiovascular disease (http://droog.gs.washington.edu/parc) (r 2 Ն0.8 in either population; minor allele frequency Ն0.05; at the time of this study, no equivalent data were available for any Chinese populations), 31 (2) to test SNPs previously reported to be associated with hypertension,* and/or (3) to include SNPs in the promoter regions. Genotyping was performed using TaqMan technology, as previously described. 36 The sequences of all primers and probes involved are available on request. Each SNP was in Hardy-Weinberg equilibrium (data not shown).
Statistical Analyses
To control for type I error attributable to multiple testing, analysis was conducted in 2 phases: First, all markers and haplotypes were tested in an exploratory sample (nϭ733); then, positive results were tested in a confirmatory sample (nϭ714). The 2 samples were randomly selected from the total of 1447 subjects. For quantitative variables, the univariate comparisons between groups were tested by the Student t test when variables had a normal distribution, or by nonparametric Wilcoxon rank test when variables deviated from normal distribution. We used the 2 test to compare proportions of qualitative variables between groups. Pairwise linkage disequilibrium (LD; DЈ and r 2 ) between SNPs were calculated with Haploview software. 37 Univariate and multiple regression analyses were performed for single SNPs as well as for haplotypes with a frequency Ն3%. Further analysis of AGTR1 haplotype 2 (H2) and haplotype 3 (H3) was conducted by dividing subjects into 3 groups: H2 present/H3 absent (H2/non-H3), H3 present/H2 absent (H3/non-H2), and both H2 and H3 absent (non-H2/non-H3). Because of small sample size, H2/H3 heterozygotes (nϭ9 from exploratory set, nϭ7 from confirmatory set) were deleted from further analysis. The association of response was then tested using the groups as ordinal variables: H2/non-H3ϭϪ1, non-H2/non-H3ϭ0, and H3/non-H2ϭϩ1. BP reduction was used as the outcome variable for multiple regression and gender, age, baseline BP, maximal dosage of benazepril, and kidney function (blood urea nitrogen and creatinine) as covariates. Covariates with significance Ͻ0.05 in stepwise regression were retained in the final model. R 2 was calculated to estimate the proportion of explained variation of the outcome variable as a function of the independent variable in the regression model. To test the interactions between gender and haplotypes, analyses by the stratum of gender were also performed, and the interaction term of gender-by-haplotypes was added in the regression model. The probability value of the coefficient of SNPs/haplotypes in the regression model was estimated and presented in the results. All statistical analyses were performed with SAS statistical software (V8, SAS Institute, Cary, NC).
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Clinical Characteristics
The randomly divided exploratory group (nϭ733) and confirmatory group (nϭ714) were similar in demographic and clinical characteristics (Table 1) as well as allele (Table I ) and haplotype frequencies (Table 2 ).
SNPs and Haplotypes of AGT, AGTR1, and AGTR2
AGT All 4 AGT SNPs were in strong LD (DЈՆ0.9, PϽ0.001); because rs5051 and rs699 were in complete LD, only results from rs699 are presented here. Four haplotypes comprise approximately 99% of observed haplotypes (Table 2 ).
AGTR1
Two groups of SNPs were in tight LD with each other (rs1492078, rs2638362, and rs2640543; and rs389566, rs275649, rs5182, and rs5186; Table II ). Six haplotypes comprise approximately 85% of observed haplotypes (Table 2) .
AGTR2
All 3 SNPs were in strong LD (DЈϾ0.97, PϽ0.001). Because AGTR2 is located on the X chromosome, 38 haplotypes were constructed separately for males and females, and similar frequencies were observed for each gender. Three haplotypes comprise 97% of observed haplotypes (Table 3) .
AGT SNP rs7079 and BP Reduction
Under both a dominant and additive model for association analysis of single SNPs, in the exploratory group, AGT SNP rs7079 was associated with a reduction in DBP in response to ACEI therapy: CC homozygotes showed a decreased DBP reduction compared with those with either AA or AC genotypes (Table 4 and benazepril dose. This association was further observed in the confirmatory group and in both sets combined ( Figure  2A) . Furthermore, as shown in Figure 2A , the same trend was found for both SBP and DBP response, but the difference for SBP was only statistically significant in the total sample (Pϭ0.04). The total variation of the SBP reduction explained by rs7079 was 13%; for DBP reduction, it was 9.6% (R 2 in total sample). There was no association between BP reduction in response to ACEI therapy and for any of the AGTR1 or AGTR2 individual SNPs (data not shown). Table 5 , among the 4 common haplotypes in the AGT gene, H2 showed a trend toward a greater DBP reduction in response to ACEI therapy (Pϭ0.086) in the exploratory group and an association in the confirmatory group (Pϭ0.038; combined Pϭ0.019; Figure 2B ). H2 is the only haplotype with allele A of rs7079, but it shows a less significant association with BP reduction; thus, the H2 association may be secondary to the effect of rs7079 allele A or to an untested allele in strong LD with allele A.
Haplotypes and BP Reduction
AGT
As shown in
AGTR1
AGTR1 H2 and H3 seemed to be associated with BP reduction (H2 with SBP, Pϭ0.04; H3 with DBP, Pϭ0.04; Table 5 ). After adjusting for baseline BP, the probability values of the associations between H2 carriers and SBP reduction and between H3 carriers and DBP reduction were of borderline statistical significance (Pϭ0.09 and 0.08, respectively). To estimate the effects of both AGTR1 H2 and AGTR1 H3 compared with those of non-H2 and non-H3 carriers, we divided the subjects into 3 groups based on their combinations of haplotypes (details in Methods), and we performed multiple regression analysis using the 3 AGTR1 haplotype groups as ordinal variables and adjusting for other covariates, including baseline BP (Figure 3) . In both the exploratory and confirmatory analysis, the AGTR1 haplotype combination was associated with a reduction of SBP (exploratory, Pϭ0.05; confirmatory Pϭ0.045; combined Pϭ0.004; Figure 3 , upper panel). In the total sample, the means (ϮSD) of SBP reduction for each group were 13.6Ϯ16.7 mm Hg (nϭ219) for the group with H2, 10.9Ϯ15.4 mm Hg (nϭ1112) for the group with neither H2 nor H3, and 6.6Ϯ16.0 (nϭ100) for the group with H3. A similar trend in DBP reduction was observed with the same haplotype groups, but this observation was statistically significant only when the subjects were combined (Pϭ0.035; Figure 3, lower panel) . In this analysis, the AGTR1 haplotype groups explained 13% of the total reduction in SBP and 9% of the total reduction of DBP in response to ACEI therapy. In addition to baseline SBP and BP reduction, only gender exhibited a significant difference among the 3 AGTR1 groups (Pϭ0.002) (Table III ). An interaction test demonstrated that gender did not interact with BP reduction among the 3 AGTR1 groups (all PϾ0.15, data not shown). Thus, we concluded that the effect of the AGTR1 haplotypes was present even after adjustment for any possibly confounding variables.
AGTR2
The presence of AGTR2 H2 showed a trend toward SBP response in females in the exploratory set (Table 6 ), but this association was not observed in the confirmatory set (data not shown).
Discussion
In the present study of subjects undergoing 3 years of benazepril therapy, we have observed an association between response to ACEI therapy and AGT SNP rs7079 and 2 AGTR1 haplotypes (H2 and H3). These associations remained after adjustment for multiple comparisons as well as for potential confounding factors including baseline BP. Multiple regression analysis showed that these associations accounted for a sizable amount of the variation in response to ACEI therapy, in the range of 13% of SBP and 9% to 9.6% of DBP.
We have confirmed previously reported linkage disequilibrium across AGT between 2 SNPs (rs5051 in the promoter and rs699 in exon 2). 39 The SNP rs699 has been associated with lowered BP in response to ACEI treatment in 1 study, 27 but not in other studies. 40, 41 In this study, 3 AGT SNPs (rs5051, rs699, and rs4762) were not associated with BP response to ACEIs; however, the minor allele frequencies of these SNPs in this Chinese population were considerably lower than in other populations (rs4762/T207M, 0.09 versus 0.19; approximately 0.18 versus 0.39 to 0.46 for rs699/ T268M and rs5051/Ϫ6AϪϾG). 16 However, AGT was associated here with response to ACEI therapy: AGT SNP rs7079 was associated with DBP reduction. This SNP describes C-to-A polymorphism and is in the 3Ј-untranslated region of the AGT gene. Around this SNP, by using the Transcription Element Search System (TESS v4.0; http://www.cbil. upenn.edu/tess), a ubiquitous factor AP4 -binding site was observed when the sequence contained the C allele. However, it lost the AP4-binding site when the sequence was replaced by the A allele in this site. Thus, the potential function of the SNP might have a relationship with a potential binding site for transcription factor AP4.
AGTR1 SNP A-1166C (rs5186) has been the most widely studied and has been associated with end-point phenotypes (eg, hypertension and myocardial infarction), 21, 34, 42 but the results have been inconsistent. 22, 43 This SNP also has been associated with SBP response to diuretic therapy in black women. 26 The current study did not observe an association between this SNP and response to ACEIs, but again, the C allele frequency is lower in the Chinese population (0.06 versus 0.29 in whites). 35, 44 Thus, the negative result with rs5186 may be attributable to this lower frequency. Because 2 common AGTR1 haplotypes (H2 and H3) were observed to be associated with BP reduction in this gene, AGTR1 variation may also play a role in ACEI response in Chinese patients. Chinese-specific variants may remain to be discovered by sequencing H2 and H3 and looking for variants in strong linkage disequilibrium with the tag SNPs for these haplotypes. Alternatively, the known AGTR1 variation may interact with the genetic background of this Chinese population in determining BP and response to ACEIs. These results further illustrate that a haplotype approach may be useful for testing the association of a phenotype with a gene when all of the genetic variations within a particular population may be unknown.
The major limitation of this study is that it was a postmarketing study rather than a randomized clinical trial, and thus it was not possible to control many confounding factors. For example, in 1501 patients analyzed, although 557 (37%) of patients were on drug therapy before enrolling in this study, their BP was not controlled at an optimum level, such that the mean baseline BP in this group was 149/93 mm Hg, and there was a subsequent, further mean reduction of 9.2 (SBP) and 6.7 (DBP) mm Hg during the surveillance. There was no effect on the analysis presented here when these 557 subjects were removed (data not shown), but a potential consequence of including subjects without a run-in period may be a reduction in the power to detect a genetic effect attributable to increased noise in the dataset. However, this reduction in power would interfere with gene-finding efforts, leading to underestimation of the observed genetic effect reported here.
In conclusion, we expect that the AGT and AGTR1 associations observed here, if confirmed, will be useful for predicting BP responses to ACEI treatment and may lead to the identification of further pharmacogenetic variations specific to Chinese populations.
